Relmada Therapeutics, Inc. RLMD Quick ratio
Quick ratio at other companies
Other financials
Where this comes from
Calculated from Relmada Therapeutics, Inc.’s reported figures.
Based on the most recent quarter.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s quick ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s quick ratio?
- Relmada Therapeutics, Inc. (RLMD) reported quick ratio of 18.3× in Q1 2026.
- How has Relmada Therapeutics, Inc.'s quick ratio changed year-over-year?
- Relmada Therapeutics, Inc.'s quick ratio increased by 245.3% year-over-year, from 5.3× to 18.3×.
- What is the long-term trend for Relmada Therapeutics, Inc.'s quick ratio?
- Over 5 years (2020 to 2025), Relmada Therapeutics, Inc.'s quick ratio has grown at a 9.3% compound annual growth rate (CAGR), from 9.4× to 14.6×.
- What does quick ratio mean?
- Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.